替吉奥联合奥沙利铂一线治疗晚期肝内胆管癌患者疗效和安全性评价

doi:10.3969/j.issn.1672-5069.2015.04.023

Abstract

Hao wensheng，Zhang dongcheng，Gui dong，et al.. Efficacy and safety of S-1 plus oxaliplatin as first-line treatment in patients with advanced intrahepatic cholangiocarcinomas[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 415-417.

References

[1] Nakanuma Y，Sato Y，Harada K，et al. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol，2010，2:419-427.
[2] Edg SB，Byrd DR，Compton CC，et al. AJCC cancer staging manual. 7th ed. Germany:Springer，2009:191-234.
[3] Razumilava N，Gores GJ. Combination of gemcitabine and cisplatin for biliary tract cancer:a platform to build on. J Hepatol，2011，54:577-578.
[4] Chong YS，Kim YK，Lee MW，et al. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol，2012，67:766-773.
[5] McGlynn KA，Tarone RE，EL-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Bilmarkers Prev，2006，15（6）:1198-1203.
[6] McLean L，Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int，2006，26:1047-1053.
[7] Corvera CU，Blumgart LH，Akhurst T，et a1. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg，2008，206（1）:57-65.
[8] Furuse J，Okusaka T，Boku N，et a1. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer:a multicenter phase II study. Cancer Chemother Pharmacol. 2008，62（5）:849-855.
[9] Lassen U，Jensen LH，Sorensen M，et a1. A Phase I-II dose escalation study of fixed-dose rate gemcitabine，oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. Acta Oncol，2011，50（3）:448-454.
[10] Valle J，Wasan H，Palmer DH，et al. Cisplatin plus gemicitabine versus gecitabine for biliary tract cancer. N Eng J Med，2010，362（14）:1273-1281.
[11] Komuta M，Govaere O，Vandecaveye V，et al. Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology，2012，55（6）:1876-1888.
[12] 徐长风，陈思翰，李凌.原发性肝癌的化疗与分子靶向治疗进展.实用肝脏病杂志，2014，17（3）：228-230.
[13] Raymond E，Chaney SG，Taamma A，et al. Oxaliplatin are view of preclinical and clinical studies. Ann Oneol，1998，9（10）:1053-1057.

Efficacy and safety of S-1 plus oxaliplatin as first-line treatment in patients with advanced intrahepatic cholangiocarcinomas

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

[1]	Huang Shiying, Liang Shuang, Wei Yanghui, et al. Efficacy of CAO chemotherapy regimen combined with high frequency focused ultrasound ablation in the treatment of children with hepatoblastoma at stage III/IV [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 569-572.
[2]	Wu Quanlin, He Yaopeng. Efficacy of ERCP-guided radiofrequency ablation combined with chemotherapy in treatment of patients with cholangiocarcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 537-540.
[3]	Tong Xin, Fan Hua. Efficacy of bicyclic alcohol on liver function in gastric cancer patients with chemotherapy-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 625-626.
[4]	Li Zongchao，Liu Yijin，Chen Yuhui，et al.. Effects of paravertebral anaesthesia on postoperative algesia and serum tumor necrosis factor-α in patients underwent hepatobiliary surgery [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 584-587.
[5]	Liu Ben，Hou Qiuyue.. Protective effect of atomolan to liver injuries in patients with acute myeloid leukemia receiving chemotherapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 717-719.
[6]	Xiong Shujun. Application of oxaliplatin and epirubicin through transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(1): 86-88.
[7]	Guo Xiuli, Yao Shiwei, Zhang Jun. Clinical effect of magnesium isoglycyrrhizinate combined with reduced glutathione in the treatment of patients with chemotherapeutic drug-induced liver injury [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 575-579.
[8]	Lyu Yufeng. Effectiveness and impact on liver functions of two different chemotherapy regimens in treatment of patients with pulmonary tuberculosis complicated by chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(5): 493-497.
[9]	Xu Changfeng, Chen Sihan, Li Ling. Progress in chemotherapy and molecular targeted therapy in the treatment of patients with primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 228-231.
[10]	Zhu Chuanlong, Li Yuwen, Li Wenting. Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 245-249.
[11]	Xu Yonghua, Xu Jingci, Yang Lixia, at al.. Application of apparent diffusion coefficient for predicting response of hepatic metastases to chemotherapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(5): 421-423.